Zimmer Biomet to acquire Monogram Technologies for ~$177M upfront plus CVR up to $12.37/share

ZIMMER BIOMET HOLDINGS, INC.

Equity value ~$177M ($4.04/share cash upfront); enterprise value ~$168M.
Common stockholders receive non-tradeable CVR up to $12.37/share if product, regulatory and revenue milestones through 2030 are met.
Acquisition neutral to adjusted EPS in 2025-2027, accretive in 2028+; expected to contribute to revenue growth beginning 2027.
Monogram's semi-autonomous TKA robot (FDA 510(k) March 2025) and fully autonomous system in development will expand Zimmer Biomet's ROSA robotics platform.
Closing expected later this year, subject to Monogram stockholder approval, regulatory clearances and other customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.